Geode Capital Management LLC Sells 21,336 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Geode Capital Management LLC cut its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 1.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,093,442 shares of the specialty pharmaceutical company's stock after selling 21,336 shares during the period. Geode Capital Management LLC owned 1.81% of Jazz Pharmaceuticals worth $134,697,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. HighPoint Advisor Group LLC boosted its holdings in shares of Jazz Pharmaceuticals by 21.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,556 shares of the specialty pharmaceutical company's stock worth $332,000 after acquiring an additional 456 shares in the last quarter. O Shaughnessy Asset Management LLC bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at $5,519,000. Allianz SE acquired a new position in Jazz Pharmaceuticals in the fourth quarter worth $29,000. Cornercap Investment Counsel Inc. bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth $518,000. Finally, Orion Portfolio Solutions LLC increased its stake in shares of Jazz Pharmaceuticals by 36.8% in the fourth quarter. Orion Portfolio Solutions LLC now owns 30,625 shares of the specialty pharmaceutical company's stock valued at $3,771,000 after buying an additional 8,235 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on JAZZ shares. Needham & Company LLC reissued a "buy" rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price target for the company from $145.00 to $179.00 in a report on Friday, March 7th. Piper Sandler reiterated an "overweight" rating and issued a $176.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright boosted their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of "Buy" and an average price target of $187.71.

Remove Ads

Insider Activity

In related news, CAO Patricia Carr sold 1,140 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the sale, the chief accounting officer now directly owns 7,012 shares in the company, valued at $966,323.72. This trade represents a 13.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Neena M. Patil sold 3,800 shares of the company's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now directly owns 33,318 shares of the company's stock, valued at approximately $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock worth $4,023,305 in the last 90 days. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Trading Down 1.5 %

NASDAQ:JAZZ traded down $1.55 on Friday, reaching $100.50. The company's stock had a trading volume of 1,707,238 shares, compared to its average volume of 781,354. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06. The business's 50-day moving average price is $129.67 and its two-hundred day moving average price is $122.68. The firm has a market cap of $6.10 billion, a PE ratio of 14.15, a PEG ratio of 1.04 and a beta of 0.42. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.